

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  04D2166077	<b>(X3) Date Survey Completed</b>  03/04/2020
<b>Name of Provider or Supplier</b>  Hull Dermatology	<b>Street Address, City, State</b>  9521 Sunset Dr, Bella Vista, AR	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D5473</b>	<p>CONTROL PROCEDURES CFR(s): 493.1256(e)(2)(g)</p> <p>(e) For reagent, media, and supply checks, the laboratory must do the following: (e) (2) Each day of use (unless otherwise specified in this subpart), test staining materials for intended reactivity to ensure predictable staining characteristics. Control materials for both positive and negative reactivity must be included, as appropriate. (g) The laboratory must document all control procedures performed.</p> <p>This STANDARD is not met as evidenced by: Through a review of the laboratory procedures, lack of documentation, and interviews with laboratory staff, it was determined the laboratory failed to document the quality of the Hematoxylin and Eosin (H and E) stain each day of use which has a potential to affect all histopathology slides reviewed. Survey findings include: A. A review of laboratory procedure manual failed to include a policy for documenting the quality of H and E staining of the slides. B. The surveyor requested documentation of stain quality but none was provided. C. In an interview, at approximately 08:45 a.m. on 3/4/20, laboratory employee #seven (as listed on the CMS 209 form) confirmed the laboratory failed to document slide and stain quality each day of testing.</p>